- Conditions
- HIV Infections
- Interventions
- PGDM1400/Placebo (3mg/kg IV), PGDM1400/Placebo (10mg/kg IV), PGDM1400/Placebo (30mg/kg IV), PGDM1400 + PGT121/Placebo (3mg/kg + 3mg/kg IV), PGDM1400 + PGT121/Placebo (10mg/kg + 10mg/kg IV), PGDM1400 + PGT121/Placebo (30mg/kg + 30mg/kg IV), PGDM1400 + PGT121 + VRC07-523LS (20mg/kg + 20mg/kg + 20 mg/kg IV), PGDM1400 + PGT121 (MTD IV)
- Biological
- Lead sponsor
- International AIDS Vaccine Initiative
- Network
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HIV Prevention
- Interventions
- LA-CAB, TDF/FTC
- Drug
- Lead sponsor
- Orlando Immunology Center
- Other
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 2 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- HIV I Infection
- Interventions
- Dolutegravir / Lamivudine Pill, Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill
- Drug
- Lead sponsor
- Charlotte-Paige Rolle, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- HIV Infection
- Interventions
- PGT121 3mg/kg IV, PGT121 10mg/kg IV, PGT121 30mg/kg IV, PGT121 3mg/kg SC, Placebo (0.9% Sodium Chloride Injection USP (Saline))
- Biological
- Lead sponsor
- International AIDS Vaccine Initiative
- Network
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- HIV/AIDS
- Interventions
- PGT121 + VRC07-523LS, PGT121 + VRC07-523LS + PGDM1400
- Biological
- Lead sponsor
- International AIDS Vaccine Initiative
- Network
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2022
- U.S. locations
- 3
- States / cities
- Orlando, Florida • Boston, Massachusetts • Houston, Texas
- Conditions
- HIV Infections
- Interventions
- Not listed
- Lead sponsor
- Orlando Immunology Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 11
- States / cities
- Fresno, California • Los Angelos, California • Tarzana, California + 7 more
- Conditions
- HIV-1-infection
- Interventions
- Fostemsavir 600 MG [Rukobia]
- Drug
- Lead sponsor
- Orlando Immunology Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Orlando, Florida